The TAILOR-PCI Trial evaluates the outcomes between genotype-guided P2Y12 inhibitor selection versus conventional prescribing on ischemic outcomes. Listen to Geoff Wall and guest, Jake Galdo, discuss the role of pharmacogenomics in patient care.

Additional Resource/Reference:

https://jamanetwork.com/journals/jama/article-abstract/2769725 

This episode is accredited for CPE. Subscribe at CEimpact (https://www.ceimpact.com/pharmacist) and claim your CE today!

See omnystudio.com/listener for privacy information.

Learn more about your ad choices. Visit megaphone.fm/adchoices